Metabolicheskie effekty prolaktina
https://doi.org/10.14341/brh20083-429-33
Abstract
Первые описания характерных для гиперпролактинемии симптомов встречаются в еще древних трактатах, в том числе в трудах Гиппократа. Попытка объединить ряд клинических особенностей в одну нозологическую форму была сделана в XIX веке. Было отмечено, что у рожавших женщин после прекращения грудного вскармливания могут длительно сохраняться лактация, отсутствовать менструации и отмечаться дегенеративные изменения полового тракта. Указанный симптомокомплекс был назван синдромом Киари–Фроммеля [1].В середине хх века Argonz и del Castillo описал вариант данного заболевания у ранее бесплодных женщин и высказал предположение о гормональной природе выявленных нарушений.
References
1. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М 2004.
2. Bole-Feysot C., Goffin V., Edery M. et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19 (3): 225–268.
3. Курляндская Р.И., Романцова Т.И. Влияние гиперпролактинемии на основные показатели жирового обмена. Леч врач 2004; 1: 6-9.
4. Greenman Y., Tordjman K., Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48 (5): 547–553.
5. Baptista T., Lacruz A., Meza T. et al. Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 2001; 46 (9): 829–834.
6. Pelkonen R., Nikkil E.A., Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 1982; 16 (4): 383–390.
7. Kiriakov A., Bulatov A.A., Elizarova G.P., Kavrykova I., Tinterova Z., Angelova S., Zaitseva N.S., Pankov I.A. Change in the blood lipoprotein spectrum in experimental Hyperprolactinemia. Probl Endokrinol (Mosk) 1991; 37 (1): 44–46.
8. Heil S.H. Sex-specific effects of prolactin on food intake by rats. Horm Behav 1999; 35 (1): 47–54.
9. Moore B.J., Gerardo-Gettens T., Horwitz B.A., Stern J.S. Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull 1986; 17 (4): 563–569.
10. Brandebourg T.D., Bown J.L., Ben-Jonathan N. Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue. Biochem Biophys Res Commun 2007; 357 (2) 408–413.
11. Ling C., Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology 2001; 142 (11): 480–490.
12. McAveney K.M., Gimble J.M., Yu-Lee L.-Y. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996; 137: 5723–5726.
13. Varma M. Effect of estradiol and progesterone on daily rhythm in food intake and feeding patterns in Fischer rats. Physiol Behav 1999; 68 (12): 99–107.
14. Heshmati H.M., Turpin G., de Gennes J.L. Chronic hyperprolactinemia and plasma lipids in women. Klin Wochenschr 1987; 65 (11): 516–519.
15. Baptista T., Contreras Q., Teneud L. et al. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatr 1998;22 (1): 187–198.
16. Noel M.B., Woodside B. Effects of systemic and central prolactin injections on food intake, weight gain, and estrous cyclicity in female rats. Physiol Behav 1993; 54 (1): 151–154.
17. Sauve D., Woodside B. Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res 2000; 868 (2): 306–314.
18. Sauve D., Woodside B. The effect of central administration of prolactin on food intake invirgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen. Brain Res 1996; 729 (1): 75–81.
19. Long Jin, Shuya Zhang, Bartolome G. Burguera et al. Leptin and Leptin receptor expression in rat and mouse pituitary cells. J Endocrinology 2000; 141 (1): 333–339.
20. Cone D.R. Editorial: the ups and downs of leptin action. Endocrinology 1999;140 (11): 4921–4922.
21. Панков Ю.А. Достижения в исследовании действия лептина на нейроны гипоталамуса. Журн эволюц биохим физиол 2000; 6: 509–514.
22. Jin H., Nip S., O’Dowd B.F., George S.R. D1 dopamine receptor activity is not altered by a mutation in the first intracellular loop. Biochim Biophys Acta 1998; 1402: (2): 165–170.
23. Gualillo O., Lago F., Garcia M. et al. Prolactin Stimulates Leptin Secretion by Rat White Adipose Tissue. Endocrinology 1999; 140 (11): 5149–5153.
24. Doknic M., Pekic S., Zarkovic M., Medic-Stojanoska M., Dieguez C., Casanueva F., Popovic V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147 (1): 77–84.
25. Mарова Е.И. Нейроэндокринология. Ярославль 1999; 506.
26. Yoshimura A., Ohkubo T., Kiguchi T. et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 1995; 14 (12): 2816–2826.
27. Isidori A.M., Strollo F., More M. et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J Clin Endocrinol Metab 2000; 85 (5): 1954–1962.
28. Ben-Jonathan N., Hugo E.R., Brandebourg T.D., LaPensee C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17 (3): 110–116.
29. Fleenor D.E., Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology 2001; 142 (7): 2805–2810.
30. Fleenor D., Arumugam R., Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res 2006; 66 (3): 101–110.
31. De Courten M., Zimmet P., Hodge A. et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997; 14 (3): 200–208.
32. Tuzcu A., Bahceci M., Dursun M. et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 2003; 26 (4): 341–346.
33. Bahceci M., Tuzcu A., Bahceci S., Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003; 26 (7): 655–659.
34. Cincotta A.H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19 (Issue 6): 667–670.
35. Fahy U., Hopton M.I., Hartog M. et al. The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Hum Reprod 1999; 14 (2): 285–287.
36. Korner J., Lo J., Freda P.U., Wardlaw S.L. Treatment with Cabergoline Is Associated with Weight Loss in Patients with Hyperprolactinemia. Obes Res 2003; 11: 311–312.
37. Bina K.G., Cincotta A.H. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71 (1): 68–78.
38. Pijl H., Ohashi S., Matsuda M. et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23 (Issue 8): 1154–1161.
Review
For citations:
Dzeranova L.K., Mokrysheva N.G., Barmina I.I., Giniyatullina E.N. Metabolicheskie effekty prolaktina. Bulletin of Reproductive Health. 2008;(3-4):29-33. (In Russ.) https://doi.org/10.14341/brh20083-429-33
Views:
802
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
